Clinical Trial Detail

NCT ID NCT02116777
Title BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lymphoid leukemia

Advanced Solid Tumor

Ewing sarcoma

Therapies

Talazoparib + Temozolomide

Age Groups: adult child

No variant requirements are available.